Clinical Guidelines

From Tissue to Treatment

Optimizing biomarker testing in prostate cancer

Share

  • 1

    Prostate cancer is the most common cancer in men in Europe.

  • 2

    Precision oncology's promise depends on biomarker testing.

  • 3

    HRR alterations affect many metastatic prostate cancer patients.

  • 4

    Localized testing practices are essential across fragmented healthcare systems.

  • 5

    Digital workflows improve testing efficiency and outcomes.

  • 6

    Rethinking testing timing can enhance sample quality.

  • 7

    Liquid biopsy offers a minimally invasive option for genetic information.

  • 8

    Continuous education and standardized processes are crucial.

Original Source(s)

From Tissue to Treatment

Optimizing biomarker testing in prostate cancer

  • by Lynda Corrigan, Stephen Finn

  • November 5, 2025

  • 7 min

Related Content

Breaking the Biomarker Bottlenecks: Part 2

Industry leaders from AstraZeneca, Leica Biosystems, and Danaher share their insights on AI’s power to democratize access to precision medicine

  • February 16, 2026

  • 9 min
Identifying HER2-low expression – A pathologist led slide review

Roche Tissue Diagnostics invites you to learn more about the importance of identifying each level of HER2 expression.

  • December 14, 2022

Democratizing Tumor Genomic Profiling With Tailored Content

Join Us With Agilent For Our Webinar On Democratizing Tumor Genomic Profiling. The webinar will discuss the range of available tumor genomic profiling assays (comprehensive, tumor-specific, customized) in the Agilent SureSelect Cancer product portfolio and much, much more!

  • June 26, 2024